Menu Search
Equities

Aequus Pharmaceuticals Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
AEQ:MUN

Aequus Pharmaceuticals Inc

Actions
  • Price (EUR)0.041
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change--
  • Beta-0.5304
Data delayed at least 15 minutes, as of May 11 2022 10:31 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Aequus Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company. The Company is focused on developing and commercializing differentiated products in ophthalmology. The Company is focused on building its Canadian commercial platform through the launch of additional products that are either created internally or brought in through an acquisition or license; remaining focused on specialized therapeutic areas. Its products include ZIMED PF and PAUL GLAUCOMA IMPLANT. PAUL is a glaucoma drainage device designed to regulate intraocular pressure in the patient’s eyes and prevent further progression of the disease and is already available in over 40 countries around the world. ZIMED PF is the first available multi-dose, preservative free, bimatoprost containing product in Canada. The Company is also developing REV-0100, which is in preclinical development as a treatment for Stargardt disease.

  • Revenue in CAD (TTM)918.47k
  • Net income in CAD-656.34k
  • Incorporated2013
  • Employees12.00
  • Location
    Aequus Pharmaceuticals IncSuite 2820, 200 Granville StreetVANCOUVER V6C 1S4CanadaCAN
  • Phone+1 (604) 336-7906
  • Fax+1 (604) 336-7906
  • Websitehttps://www.aequuspharma.ca/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.